Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient level meta-analysis. J Thromb Haemost. 2010;8(11):2436-2442. 57. Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med. 2000;160(6):769-774. 58. Schulman S, Wahlander K, Lundstr m T, Clason SB, Eriksson H; for the TIIII. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med. 2003;349(18):1713-1721. 59. Napolitano M, Saccullo G, Malato A, et al. Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study. J Clin Oncol. 2014; 32(32):3607-3612. 60. Couturaud F, Sanchez O, Pernod G, et al. Six months vs extended oral anticoagulation after a rst episode of pulmonary embolism: The PADIS-PE randomized clinical trial. JAMA. 2015;314(1): 31-40. 61. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a rst episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340(12): 901-907. 62. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low- intensity warfarin therapy for prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348(15):1425-1434. 63. Farraj RS. Anticoagulation period in idiopathic venous thromboembolism. How long is enough? Saudi Med J. 2004;25(7): 848-851. 64. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006;355(17):1780-1789. 65. Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med. 1997;336(6):393-398. 66. Douketis J, Tosetto A, Marcucci M, et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta- analysis. BMJ. 2011;342:d813. 67. Douketis J, Tosetto A, Marcucci M, et al. 